Jefferies lowered the firm’s price target on Globus Medical (GMED) to $88 from $90 and keeps a Buy rating on the shares. The firm views the company’s pre-announced results as better than feared, given disruption in Q1 and investor concerns about Nevro. Jefferies lowered estimates to above the midpoint from the high end and trimmed its price target though maintains a Buy view.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Roth MKM medical technology analyst holds analyst/industry conference call
- Verizon reports Q2 beat, Block to join S&P 500: Morning Buzz
- Roth bullish on Globus Medical amid CEO Transition, solid pre-reported results
- Hold Rating Maintained for Globus Medical Amid CEO Transition and Growth Concerns
- Globus Medical Announces New CEO and CFO